

Balaxi Pharmaceuticals Limited

Date: 28.01.2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Outcome of Board Meeting

In reference to our letter dated January 21, 2026 we wish to inform you that the Board of Directors at their meeting held today i.e., January 28, 2026, have *inter-alia*, approved the following:

1. Standalone and Consolidated Unaudited Financial Results of the Company for third quarter and nine months ended 31.12.2025

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Standalone and Consolidated Unaudited Financial Results of the Company for the third quarter and nine months ended 31.12.2025 accompanied by Limited Review Reports thereon issued by the Statutory Auditors of the Company- ***Enclosed***

2. Took note of the Company's first pharmaceutical Formulation plant at Jadcherla, Hyderabad

The Board of Directors took note of the progress of the Company's first pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad, as presented by the Managing Director.

The Board was informed that, as reported in the previous quarter, the construction and infrastructure setup of the facility had been completed and the Test Manufacturing Licence had been obtained. Key utilities were validated, vendors qualified, and test manufacturing for Paracetamol 500 mg and Piroxicam 20 mg was successfully carried out, with batches placed under stability studies.

During the current quarter, the Board was apprised that the formulation facility has achieved full readiness for the upcoming CDSCO inspection. All Manufacturing, Quality Assurance, Quality Control, and Microbiology documentation has been completed, and equipment, utility, and system qualification and validation activities have been successfully executed.

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

It was further noted that a robust cGMP-compliant Quality Management System has been fully implemented across functions, and three-month stability data for the test batches has been generated and found to be satisfactory.

The Board also noted that all open actions, deficiencies, and snag list observations have been closed during the quarter, and the facility is currently in a state of final audit readiness.

The Board expressed satisfaction with the progress achieved during the quarter and noted that the Company is well-positioned for the next phase of regulatory approvals and commencement of commercial operations.

3. Resignation of Mr.Mohith Kumar Khandelwal as the Company Secretary and Compliance officer of the Company.

The Board of Directors took note and accepted the resignation of Mr.Mohith Kumar Khandelwal from the position of Company Secretary and Compliance officer of the Company. Mr.Mohith Kumar Khandelwal shall be relieved from the services with effect from close of business hours on 29.01.2026.

The information required to be furnished under SEBI Master circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/0155 dated 11th November 2024, **-Enclosed**

The Board meeting commenced at 11.30 AM. (IST) and concluded at 02.40 PM (IST).

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,
For **Balaxi Pharmaceuticals Limited**

Mohith Kumar Khandelwal
(Company Secretary and Compliance Officer)
Membership No.: F11243

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana

CIN:L25191TG1942PLC121598

Un-audited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2025

Particulars	Quarter Ended			Nine Months Ended		(Rs. in Lakhs)
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	Year ended
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	31.03.2025 (Audited)
Income						
Revenue from operations	2,459.36	1,931.00	1,115.83	6,061.18	5,133.94	6,098.82
Other income	162.38	421.45	291.66	630.05	505.28	537.34
Total Income	2,621.74	2,352.45	1,407.49	6,691.23	5,639.22	6,636.16
Expenses						
Cost of materials consumed	2,101.64	1,650.57	930.72	5,169.80	4,272.09	5,094.16
Employee benefit expense	121.66	117.14	119.37	370.15	348.38	487.14
Finance cost	73.43	62.40	56.58	198.93	136.79	205.77
Depreciation and amortisation expense	15.30	12.34	11.38	38.92	34.47	45.60
Administrative expenses	97.80	85.79	56.00	251.48	204.83	274.72
Total Expenses	2,409.83	1,928.24	1,174.05	6,029.28	4,996.56	6,107.39
Profit/(loss) before tax and other comprehensive income	211.91	424.21	233.44	661.95	642.66	528.77
Tax expenses						
Current tax	58.57	99.39	60.99	166.08	170.22	178.20
Deferred tax	0.28	(1.54)	(1.87)	(3.04)	(5.69)	-9.56
Net Profit/(loss) for the period	153.06	326.36	174.32	498.91	478.13	360.13
Other comprehensive income						
A (i) Items that will not be reclassified to profit or loss in subsequent period	-	-	-	-	-	-
Re-measured gains on defined benefit plans	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total comprehensive income for the year	153.06	326.36	174.32	498.91	478.13	360.13
Paid up equity share capital - Face value of Rs.2 each	1,104.15	1,104.15	1,104.15	1,104.15	1,104.15	1,104.15
Other Equity						
Earnings Per Share (EPS)						
(EPS for the quarter is not annualised)						
-Basic (Amount in Rs.)	0.28	0.59	0.32	0.90	0.87	0.65
-Diluted (Amount in Rs.)	0.28	0.59	0.32	0.90	0.87	0.65

Notes :

- The Unaudited Financial Results for the Quarter ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28th January, 2026. The Standalone Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The Standalone Financial Results were reviewed by the statutory auditors and limited review report was given thereon.
- Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(c) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.

For and on behalf of Board of Directors
of Balaxi Pharmaceuticals Limited



Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad, India
Date: 28th January, 2026

Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana

CIN: L25191TG1942PLC121598

Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended 31st December, 2025

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income						
Revenue from operations	7,254.24	5,617.53	7,329.13	19,945.98	21,629.51	29,256.12
Other income	9.56	158.50	393.70	(9.60)	(202.30)	(371.64)
Total Income	7,263.79	5,776.03	7,722.83	19,936.38	21,427.21	28,884.48
Expenses						
Cost of materials consumed	4,173.53	2,902.94	4,383.85	11,032.45	12,614.38	16,570.09
Employee benefit expense	1,021.28	893.38	931.28	2,755.89	2,584.64	3,473.96
Finance cost	101.57	89.22	137.73	291.40	219.90	293.46
Depreciation and amortisation expense	55.95	48.45	47.89	150.64	143.36	189.46
Administrative Expenses	1,750.49	1,704.35	1,615.16	5,316.99	3,964.23	5,490.55
Total Expenses	7,102.82	5,638.34	7,115.90	19,547.37	19,526.52	26,017.52
Profit/(loss) before tax and other comprehensive income	160.98	137.69	606.92	389.00	1,900.69	2,866.96
Tax expenses						
Current tax	130.20	118.33	72.51	311.63	263.12	369.50
Deferred tax	0.28	(1.54)	(1.87)	(3.04)	(5.69)	(9.56)
Net Profit/(loss) for the period	30.50	20.90	536.28	80.41	1,643.26	2,507.02
Other comprehensive income						
A (i) Items that will not be reclassified to profit or loss in subsequent period						
Exchange differences on translation of foreign operations	167.89	471.69	228.86	747.85	301.92	254.78
(ii) Income tax relating to items that will not be reclassified to profit or loss						
B (i) Items that will be reclassified to profit or loss						
(ii) Income tax relating to items that will be reclassified to profit or loss						
Total comprehensive income for the year	198.39	492.60	765.14	828.26	1,945.18	2,766.80
Paid up equity share capital - Face value of Rs. 2 each	1,104.15	1,104.15	1,104.15	1,104.15	1,104.15	1,104.15
Other Equity						
Earnings Per Share (EPS)	0.03					
(EPS for the quarter is not annualised)						
-Basic (Amount in Rs.)	0.06	0.04	0.97	0.15	2.98	4.54
-Diluted (Amount in Rs.)	0.06	0.04	0.97	0.15	2.98	4.54

Notes :

- The Unaudited Consolidated Financial Results for the Quarter and Year ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28th January, 2026. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The Standalone Financial Results were reviewed by the statutory auditors and limited review report was given thereon.
- Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.

Place: Hyderabad, India
Date: 28th January, 2026



For and on behalf of Board of Directors
of Balaxi Pharmaceuticals Limited

Ashish Maheshwari
Managing Director
DIN: 01575984



P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com


Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review report to
The Board of Directors
Balaxi Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **BALAXI PHARMACEUTICALS LIMITED** (the "Company") for the quarter ended 31st December, 2025 and for the period from 01st April 2025 to 31st December 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

M.V. Joshi

Partner

M.No. 024784

UDIN: 26024784RSSMWJ4208



Place: Hyderabad

Date: 28-01-2026.



P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com
Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review report to
The Board of Directors
Balaxi Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited consolidated financial results of **BALAXI PHARMACEUTICALS LIMITED** (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), for the quarter ended 31st December, 2025 and for the period from 01st April 2025 to 31st December 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entity:

1. Balaxi Global FZCO, Dubai (Wholly owned subsidiary) which includes its following wholly owned Subsidiaries:
 - a) Balaxi Healthcare Guatemala, S.A, Dominican Republic (wholly owned subsidiary of Balaxi Global DMCC, Dubai)
 - b) Balaxi Healthcare Dominican, S.R.L, Dominican Republic (wholly owned subsidiary of Balaxi Global DMCC, Dubai)
 - c) Balaxi Healthcare, Honduras, S DE RL DE CV(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
 - d) Balaxi Healthcare Nicaragua (wholly owned subsidiary of Balaxi Global DMCC, Dubai)
 - e) Balaxi Healthcare El Salvador SA DE(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
 - f) Balaxi Healthcare Angola(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
2. M/s. Balaxi Healthcare Ecuador S.A.S (Wholly Owned Subsidiary)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

Two Wholly owned subsidiaries, whose interim Ind AS financial results and other financial information reflect total assets of Rs. 29,938.66 lakhs as at 31st December 2025 and total revenue of Rs. 7,254.24 lakhs and Rs. 19,945.98 lakhs, total net profit after tax of Rs. 61.21 lakhs and Rs. (169.16) lakhs and total comprehensive income of Rs. 33.01 lakhs and Rs. (169.23) lakhs for the quarter ended 31st December 2025 and for the period from 01st April 2025 to 31st December 2025, respectively, as considered in "the Statement" whose interim Ind AS financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on the Statement in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

M.V. Joshi

Partner

M.No. 024784

UDIN: 26024784DXHPOP5368



Place: Hyderabad

Date: 28-01-2026.

Balaxi Pharmaceuticals Limited

Details required under SEBI Master Circular SEBI/HO/CFD/CFD-PoD2/CIR/P/0155 dated November 11,2024

Changes in Directors, Key Managerial Personnel and Senior Management

Sno.	Particulars	Remarks
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation as the Company Secretary and compliance officer of the Company to pursue opportunities outside organisation
2.	Date of appointment/ cessation (as applicable) & term of appointment/re-appointment	29.01.2026. Mr.Mohith Kumar Khandelwal shall be relieved from the services of the Company with effect from close of business hours on 29.01.2026.
3.	Brief Profile (in case of appointment)	Not applicable
4.	Disclosure of relationships between directors (in case of appointment)	Not applicable

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Resignation Letter

Date: 28.01.2026

To

The Board of Directors

Balaxi Pharmaceuticals Limited

Plot No.409, H.No.8-2-293,Maps Towers

3rd floor,Phase -III Jubilee Hills

Hyderabad- 500 096

Telangana.

Sub: Resignation from the position of Company Secretary and Compliance officer of the Company

Respected Board Members,

With reference to the above-mentioned subject, i hereby tender my resignation as Company Secretary and Compliance Officer and all other statutory/ designated positions in the Company as I wish to pursue an alternate career opportunity outside of the Company.


I confirm that there is no other material reason other than to pursue an alternate career opportunity outside of the Company. I request the Board of Directors to accept my resignation and relieve me from my duties with effect from close of business hours on 29.01.2026.

I hereby convey my sincere thanks to the Board of Directors and Management of the Company for their unstinted support and cooperation extended during my tenure as Company Secretary and Compliance Officer of the Company.

Wishing the Company the very best for the years ahead.

Thanking You.

Sincerely,



Mohith Kumar Khandelwal

Company Secretary and Compliance officer

M.No:F11243